Health Economist Calls for New Payment Infrastructure for Gene Therapies
Health economist William Padula argues that high-cost gene therapies, including treatments costing $2 million or more, require new financing models to enable patient access. The commentary asserts that the barrier to deploying curative therapies is not scientific but financial and infrastructural. Padula contends that existing payment systems are ill-equipped to handle the upfront costs of one-time curative treatments. The piece calls for innovative financing mechanisms to bridge the gap between therapeutic breakthroughs and patient access.
Medicaid managed care organizations face growing pressure to cover costly gene therapies while managing capitated budgets, making alternative payment models and risk-sharing arrangements operationally critical.
Pharmacy · Managed Care · Finance
You might also like